tirzepatide week 12 weight loss percentage reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 Retatrutide vs. Tirzepatide: Unveiling the

Description

The SURMOUNT-5 trial, published in early 2025, compared tirzepatide directly with semaglutide for weight loss and found that participants on tirzepatide lost significantly more weight on average

Focus on balanced nutrition with adequate protein, as reduced appetite during treatment may sometimes lead to insufficient protein intake

Embrace recommended lifestyle interventions

demonstrate it significantly lowers ICP both acutely, achieving a reduction of approximately 5.7 cmCSF within 2.5 h, and sustains this effect long-term, with a sustained reduction of 5.6 cmCSF noted at 12 weeks

Dosage and Titration Schedule Mounjaro is started at a low initial dose to help minimise side effects, particularly gastrointestinal symptoms such as nausea